{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:11:42Z","timestamp":1787238702342,"version":"build-2736575974"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The United Kingdom introduced meningococcal serogroup C conjugate (MCC) vaccines in 1999, resulting in substantial declines in serogroup C disease and carriage. Here, we measured the age-specific prevalence of serum bactericidal antibodies (SBA) to\n                    <jats:italic>Neisseria meningitidis<\/jats:italic>\n                    serogroup C and immunoglobulin G (IgG) concentrations to serogroups A, C, W-135, and Y in 2,673 serum samples collected in England between 2000 and 2004. We compared the seroprevalence of SBA titers of \u22658 in the postvaccination era with results from an earlier prevaccination study conducted using the same methods. We found that the percentages of individuals with protective SBA titers were higher in 2000 to 2004 in all of the age groups targeted for MCC vaccination. In the postvaccine era, the prevalence of protective titers was high (75%) in children who had recently been offered routine immunization, but this fell to 36% more than 18 months after scheduled immunization. In the cohorts targeted in the catch-up campaign, the percentage achieving SBA titers of \u22658 was higher in children offered the vaccine at ages 5 to 17 years than in children offered the vaccine at ages 1 to 4 years. The geometric mean concentration (GMC) IgG for serogroup C followed a similar pattern, corresponding to the age at and time since scheduled MCC vaccination. Serogroup-specific IgG GMCs for W-135 and Y were low and showed little variation by age. Serogroup A IgG GMCs were higher, possibly reflecting exposure to cross-reacting antigens. Although the incidence of serogroup C disease remains low due to persisting herd effects, population antibody levels to serogroup C meningococci should be monitored so that potentially susceptible age groups can be identified should herd immunity wane.\n                  <\/jats:p>","DOI":"10.1128\/cvi.00279-08","type":"journal-article","created":{"date-parts":[[2008,9,30]],"date-time":"2008-09-30T23:29:11Z","timestamp":1222817351000},"page":"1694-1698","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":60,"title":["Seroprevalence of Antibodies against Serogroup C Meningococci in England in the Postvaccination Era"],"prefix":"10.1128","volume":"15","author":[{"given":"Caroline L.","family":"Trotter","sequence":"first","affiliation":[{"name":"Department of Social Medicine, University of Bristol, Bristol, United Kingdom"},{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Statistics Unit, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"},{"name":"Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Department of Social Medicine, University of Bristol, Bristol, United Kingdom"},{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Statistics Unit, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"},{"name":"Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[{"name":"Department of Social Medicine, University of Bristol, Bristol, United Kingdom"},{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Statistics Unit, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"},{"name":"Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Holland","sequence":"additional","affiliation":[{"name":"Department of Social Medicine, University of Bristol, Bristol, United Kingdom"},{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Statistics Unit, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"},{"name":"Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Frankland","sequence":"additional","affiliation":[{"name":"Department of Social Medicine, University of Bristol, Bristol, United Kingdom"},{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Statistics Unit, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"},{"name":"Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick J.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Department of Social Medicine, University of Bristol, Bristol, United Kingdom"},{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Statistics Unit, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"},{"name":"Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Social Medicine, University of Bristol, Bristol, United Kingdom"},{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Statistics Unit, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"},{"name":"Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"780","volume":"10","year":"2003","unstructured":"Andrews, N., R. Borrow, and E. Miller. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol.10:780-786.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.3.1568-1573.2001"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","year":"2005","unstructured":"Borrow, R., P. Balmer, and E. Miller. 2005. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine23:2222-2227.","journal-title":"Vaccine"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/14760584.5.6.851","volume":"5","year":"2006","unstructured":"Borrow, R., and E. Miller. 2006. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev. Vaccines5:851-857.","journal-title":"Expert Rev. Vaccines"},{"key":"e_1_3_2_6_2","unstructured":"Department of Health. 8 February 2006. Planned changes to the routine childhood immunisation schedule. Department of Health London United Kingdom. http:\/\/www.dh.gov.uk\/assetRoot\/04\/12\/81\/21\/04128121.pdf\/\n."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1017\/S0950268800058209","volume":"115","year":"1995","unstructured":"Gay, N. J., L. M. Hesketh, P. Morgan-Capner, and E. Miller. 1995. Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy. Epidemiol. Infect.115:139-156.","journal-title":"Epidemiol. Infect."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","year":"1969","unstructured":"Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med.129:1307-1326.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","volume":"55","year":"2006","unstructured":"Gray, S. J., C. L. Trotter, M. E. Ramsay, M. Guiver, A. J. Fox, R. Borrow, R. H. Mallard, and E. B. Kaczmarski. 2006. Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol.55:887-896.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1084\/jem.162.6.1837","volume":"162","year":"1985","unstructured":"Guirguis, N., R. Schneerson, A. Bax, W. Egan, J. B. Robbins, J. Shiloach, I. Orskov, F. Orskov, and A. el Kholy. 1985. Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies. J. Exp. Med.162:1837-1851.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.2.2.132-137.1995"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bjc.6603955","volume":"97","year":"2007","unstructured":"Jit, M., A. Vyse, R. Borrow, R. Pebody, K. Soldan, and E. Miller. 2007. Prevalence of human papillomavirus antibodies in young female subjects in England. Br. J. Cancer97:989-991.","journal-title":"Br. J. Cancer"},{"key":"e_1_3_2_13_2","first-page":"1","volume":"11","year":"2004","unstructured":"Joseph, H., P. Balmer, M. Bybel, T. Papa, R. Ryall, and R. Borrow. 2004. Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera. Clin. Diagn. Lab. Immunol.11:1-5.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1016\/S0264-410X(02)00255-4","volume":"20","year":"2002","unstructured":"Kelly, H., M. A. Riddell, H. F. Gidding, T. Nolan, and G. L. Gilbert. 2002. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine20:3130-3136.","journal-title":"Vaccine"},{"key":"e_1_3_2_15_2","first-page":"272","volume":"11","year":"2004","unstructured":"Lal, G., P. Balmer, H. Joseph, M. Dawson, and R. Borrow. 2004. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135. Clin. Diagn. Lab. Immunol.11:272-279.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1086\/527401","volume":"197","year":"2008","unstructured":"Maiden, M. C., A. B. Ibarz-Pavon, R. Urwin, S. J. Gray, N. J. Andrews, S. C. Clarke, A. M. Walker, M. R. Evans, J. S. Kroll, K. R. Neal, D. A. Ala'Aldeen, D. W. Crook, K. Cann, S. Harrison, R. Cunningham, D. Baxter, E. Kaczmarski, J. MacLennan, J. C. Cameron, and J. M. Stuart. 2008. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis.197:737-743.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","volume":"359","year":"2002","unstructured":"Maiden, M. C. J., and J. M. Stuart on behalf of the UK Meningococcal Carriage Group. 2002. Carriage of serogroup C meningococci one year after meningococcal C conjugate polysaccharide vaccination. Lancet359:1829-1830.","journal-title":"Lancet"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.4.2.156-167.1997"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/bmj.329.7467.655","volume":"329","year":"2004","unstructured":"McVernon, J., C. L. Trotter, M. P. Slack, and M. E. Ramsay. 2004. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ329:655-658.","journal-title":"BMJ"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","volume":"20","year":"2001","unstructured":"Miller, E., D. M. Salisbury, and M. E. Ramsay. 2001. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20:S58-S67.","journal-title":"Vaccine"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/jmv.10132","volume":"67","year":"2002","unstructured":"Morris, M. C., W. J. Edmunds, L. M. Hesketh, A. J. Vyse, E. Miller, P. Morgan-Capner, and D. W. Brown. 2002. Sero-epidemiological patterns of Epstein-Barr and herpes simplex (HSV-1 and HSV-2) viruses in England and Wales. J. Med. Virol.67:522-527.","journal-title":"J. Med. Virol."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.8.6.896-900.1973"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/ije\/29.2.362","volume":"29","year":"2000","unstructured":"Osborne, K., N. J. Gay, L. Hesketh, P. Morgan-Capner, and E. Miller. 2000. Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int. J. Epidemiol.29:362-368.","journal-title":"Int. J. Epidemiol."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1086\/376997","volume":"188","year":"2003","unstructured":"Ramsay, M. E., J. McVernon, N. J. Andrews, P. T. Heath, and M. P. Slack. 2003. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J. Infect. Dis.188:481-485.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","volume":"326","year":"2003","unstructured":"Ramsay, M. E., N. J. Andrews, C. L. Trotter, E. B. Kaczmarski, and E. Miller. 2003. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ326:365-366.","journal-title":"BMJ"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.6.5.651-656.1972"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","volume":"24","year":"2005","unstructured":"Snape, M. D., D. F. Kelly, B. Green, E. R. Moxon, R. Borrow, and A. J. Pollard. 2005. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr. Infect. Dis. J.24:128-131.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","volume":"336","year":"2008","unstructured":"Snape, M. D., D. F. Kelly, S. Lewis, C. Banner, L. Kibwana, C. E. Moore, L. Diggle, T. John, L. M. Yu, R. Borrow, A. Borkowski, C. Nau, and A. J. Pollard. 2008. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ336:1487-1491.","journal-title":"BMJ"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0264-410X(02)00630-8","volume":"21","year":"2003","unstructured":"Trotter, C., R. Borrow, N. Andrews, and E. Miller. 2003. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine21:1094-1098.","journal-title":"Vaccine"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","volume":"364","year":"2004","unstructured":"Trotter, C. L., N. J. Andrews, E. B. Kaczmarski, E. Miller, and M. E. Ramsay. 2004. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet364:365-367.","journal-title":"Lancet"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/aje\/kwi160","volume":"162","year":"2005","unstructured":"Trotter, C. L., N. J. Gay, and W. J. Edmunds. 2005. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am. J. Epidemiol.162:89-100.","journal-title":"Am. J. Epidemiol."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0140-6736(03)13172-8","volume":"361","year":"2003","unstructured":"Trotter, C. L., J. McVernon, N. J. Andrews, M. Burrage, and M. E. Ramsay. 2003. Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet361:1523-1524.","journal-title":"Lancet"},{"key":"e_1_3_2_33_2","first-page":"220","volume":"5","year":"2002","unstructured":"Trotter, C. L., M. E. Ramsay, and E. B. Kaczmarski. 2002. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun. Dis. Public Health5:220-225.","journal-title":"Commun. Dis. Public Health"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1017\/S0950268807007856","volume":"135","year":"2007","unstructured":"Vyse, A. J., N. J. Andrews, L. M. Hesketh, and R. Pebody. 2007. The burden of parvovirus B19 infection in women of childbearing age in England and Wales. Epidemiol. Infect.135:1354-1362.","journal-title":"Epidemiol. Infect."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1017\/S0950268804003140","volume":"132","year":"2004","unstructured":"Vyse, A. J., N. J. Gay, L. M. Hesketh, P. Morgan-Capner, and E. Miller. 2004. Seroprevalence of antibody to varicella zoster virus in England and Wales in children and young adults. Epidemiol. Infect.132:1129-1134.","journal-title":"Epidemiol. Infect."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00279-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00279-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T11:54:28Z","timestamp":1627559668000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00279-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1128\/CVI.00279-08"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00279-08","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"2008-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-09-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}